PALBOTOR 75 MG CAPS 21'S

About

PALBOTOR is an oral cyclin-dependent kinase (CDK) 4 and 6 inhibitor, representing a significant advancement in targeted therapy for hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced or metastatic breast cancer. This medication works by selectively inhibiting CDK4 and CDK6, key enzymes that regulate cell cycle progression. In cancer cells, these kinases are often overactive, driving uncontrolled proliferation. By blocking CDK4 and CDK6, PALBOTOR prevents the phosphorylation of retinoblastoma protein (Rb), which is essential for the cell to transition from the G1 phase to the S phase of the cell cycle. This inhibition effectively halts cell proliferation and induces cellular senescence, thereby slowing down tumor growth and progression. PALBOTOR is typically used in combination with endocrine therapy, such as an aromatase inhibitor or fulvestrant, to enhance its therapeutic effect and improve progression-free survival in eligible patients.

Uses

• HR+, HER2- advanced or metastatic breast cancer.
• Used in combination with an aromatase inhibitor.
• Used in combination with fulvestrant.
• For postmenopausal women or men.

Directions For Use

Take orally once daily with food for 21 consecutive days, followed by 7 days off, to complete a 28-day cycle.

Benefits

• Significantly improves progression-free survival.
• Delays the need for cytotoxic chemotherapy.
• Targeted therapy with a specific mechanism of action.
• Oral administration for patient convenience.
• Effective in a specific breast cancer subtype.
• Can be combined with endocrine therapies.

Side Effects

• Neutropenia (low white blood cell count)
• Fatigue and asthenia
• Nausea and vomiting
• Stomatitis (mouth sores)
• Diarrhea
• Alopecia (hair thinning or loss)
• Infections (e.g., upper respiratory tract infections)
• Anemia (low red blood cell count)
• Thrombocytopenia (low platelet count)
• Rash
• Decreased appetite
• Headache

Safety Measures

• Alcohol - No specific contraindication, but moderation is advised; discuss with your doctor.
• Pregnancy - Contraindicated during pregnancy due to potential for fetal harm; use effective contraception.
• Breastfeeding - Not recommended during breastfeeding as the drug may be excreted in breast milk.
• Liver - Dose adjustment may be necessary for patients with severe hepatic impairment; monitor liver function.
• Kidney - Dose adjustment may be necessary for patients with severe renal impairment; monitor kidney function.
• Lung - Rare cases of interstitial lung disease/pneumonitis reported; monitor for new or worsening respiratory symptoms.

Disclaimer

MedEHub is committed to delivering reliable, expert-reviewd information to help consumers make informed health decisions. However, the content provided on this website is for informational purposes only and is not intended to replace professional medical advice, diagnosis or treatment.

Always consult your doctor for any medical concerns, and discuss your questions about health conditions or medications with a qualified healthcare professional. Do not ignore or delay seeking professional medical advice based on information found on Med E Hub.

Our goal is to complement, not replace, the essential doctor-patient relationship.